Myostatin is a negative regulator of muscle mass. The impact of myostatin deficiency on the contractile properties of healthy muscles has not been determined. We hypothesized that myostatin deficiency would increase the maximum tetanic force (P o ), but decrease the specific P o (sP o ) of muscles and increase the susceptibility to contraction-induced injury. 
Introduction
Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-β) family of cytokines and functions as a negative regulator of skeletal muscle mass. Inactivation of the myostatin genes and post-natal inhibition of myostatin both result in significant increases in skeletal muscle mass (4, 5, 21, 42, 47, 65, 68, 69) . Systemic and skeletal muscle specific overexpression of myostatin induce skeletal muscle atrophy (52, 71).
The Belgian Blue and Piedmontese breeds of cattle have a mutated form of the myostatin gene and are characterized by larger skeletal muscles than other breeds (20, 24) . At the time of birth, a human child with apparent null mutations in his myostatin genes had a thigh muscle volume two-fold greater in size than ten age-matched controls (54) . The child's mother, who is heterozygous for the mutation, was also reported to be hypermuscular (54) .
Myostatin circulates through the blood in a latent form bound to its propeptide and to follistatin (2) . The myostatin gene (MSTN) encodes a precursor protein that undergoes proteolytic processing to generate a propeptide and a mature myostatin dimer (67). The propeptide binds myostatin noncovalently and inhibits the bioactivity of myostatin (42, 57, 67) . Cleavage of the propeptide by the BMP-1/tolloid family of metalloproteinases results in the liberation and activation of myostatin (67). Activated myostatin binds to appear to be more responsive to the myostatin signaling pathway than type I muscles, but the mechanism responsible for this difference is unknown (10, 37, 41, 43) .
The inhibition of myostatin may be useful in the treatment of muscle injuries and muscle wasting diseases by improving the contractile properties of muscle (17, 26, 45, 53, 55, 59, 61) . Compared with wild type mice, myostatin deficient mice have increased bite force (9) and gross grip strength (65) . Treating mdx mice with an antibody against myostatin increased the maximum tetanic force (P o ) of EDL muscles, but did not change the specific maximum tetanic force (sP o ) (4) . When mdx mice were treated with the propeptide of myostatin, both the P o and sP o of EDL muscles increased (5) .
Myostatin may also be useful in treating muscle injuries and disease by regulating the collagen accumulation and scar tissue formation in the extracellular matrix (ECM) (17, 45) . In addition to enhancing the contractile properties of dystrophic muscle, the deficiency of myostatin decreased the accumulation of scar tissue and ECM of mdx mice (4, 5, 63) . Type I collagen is a major component of muscle ECM (31) . The transcripts of two separate genes, col1α1 and col1α2, are used to synthesize the collagen I precursor molecule, procollagen I. Procollagen I is secreted into the ECM where it undergoes cleavage and assembly to form mature collagen I (27) . TGF-β has a well established role as a positive regulator of type I collagen protein synthesis via the Smad2/3 and p38-MAPK signaling pathways (reviewed in (60)). As myostatin is a member of the TGF-β family of cytokines and utilizes similar signal transduction While a few studies have examined the effects of myostatin deficiency on the contractile properties and ECM of dystrophic muscles (4, 5, 63) , how myostatin deficiency impacts on healthy, non-dystrophic muscle is unknown. The overall aim of this study was to determine the effect of myostatin deficiency on the contractile properties, susceptibility to contraction-induced injury and collagen composition of skeletal muscle tissue. As increases in P o due to hypertrophy of muscle fibers often results in a corresponding decrease in sP o (15, 25, 30) , we hypothesized that a deficiency of myostatin would increase the P o , but decrease the sP o . Based upon the observations that myostatin deficiency decreased the ECM accumulation in dystrophic muscle (4, 5, 63) , and the similarities between the myostatin and TGF-β signal transduction pathways (29, 46, 50, 70), we formed the hypothesis that myostatin deficient mice would have less muscle ECM and that myostatin would directly increase type I collagen expression in skeletal muscle tissue. If these assumptions proved to be correct, we hypothesized that the deficiency of myostatin would increase the force deficits of muscles following a protocol of damaging lengthening contractions.
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Materials and Methods
Animals
All experiments were conducted in accordance with the guidelines of the University of Michigan Committee on the Use and Care of Animals. Mice were housed in specificpathogen-free conditions and fed food and water ad libidum. MSTN -/-mice of a C57BL/6 background were a generous gift of Dr. Se-Jin Lee. The MSTN null allele was generated by replacing the portion of the third exon of the MSTN gene that encodes the 
Fiber Counts of Muscles
To determine the number of fibers present in muscles, the extracellular matrices of muscles were digested as described (38) . Briefly, muscles were placed in a 15% HNO 3 solution overnight at room temperature. Following digestion, the HNO 3 solution was replaced with phosphate buffered saline. Individual muscle fibers were teased apart from bundles and counted under a dissecting microscope. The lengths of forty individual fibers per muscle were measured using digital calipers.
Measurement of Maximum Isometric Tetanic Force
Each muscle was immersed in the bath solution and the distal tendon was attached to a servo motor (model 305B, Aurora Scientific, Aurora, ON (6) . The physiological CSA of muscles was determined by dividing the mass of the muscle by the product of L f and 1.06 g/cm 3 , the density of mammalian skeletal muscle.
Contraction-Induced Injury
Following measurement of P t and P o , a mechanical injury to muscles was produced by two 40% lengthening contractions (7, 11, 14) . Muscles were stimulated and held at L o for 100 ms for EDL muscles and 300 ms for soleus muscles to allow muscles to develop 
Measurement of Lengths of Tibias
Hindlimbs from euthanized mice were stripped of gross muscle and connective tissue and placed in 20% hydrogen peroxide at 55°C overnight to remove remaining soft tissue. Photographic images of tibias were analyzed with ImageJ (version 1.34, NIH, Bethesda, MD) to determine length.
Hydroxyproline Assay
Hydroxyproline content of muscles was measured as described by Woessner (66).
Muscles were dried for 90 min at 110ºC and hydrolyzed in 500 µL of 6 M hydrochloric acid for 3.5 hours. The hydrolysate was neutralized with an equal volume of 6 M sodium hydroxide. Known amounts of purified L-hydroxyproline (Sigma, St. Louis, MO)
were used to construct a standard curve. Samples were assayed in triplicate using a Genios plate reader (Tecan, Mannedorf, Switzerland) at an absorbance of 560 nm.
Histology
Muscles were cryosectioned at their mid-belly and stained with Masson's Trichrome.
The areas of 100 muscle fibers randomly selected from sections of three muscles of each of the three genotypes were measured using ImageJ.
ActRIIB Immunoblot
Muscles that did not undergo assessments of the contractile properties were homogenized in cold Laemmli's sample buffer with 1:20 β-mercaptoethanol and 1:20 protease inhibitor cocktail (Sigma) and then placed in boiling water for 5 minutes.
Protein concentration of the samples was determined using an RC DC Protein Assay (Bio-Rad, Hercules, CA). Equal amounts of protein were loaded into two 4% stacking, 7.5% separating polyacrylamide gels and subjected to electrophoresis. To verify equal protein loading, gels that were not used in immunoblotting were stained with Coomassie Brilliant Blue (Bio-Rad). Proteins were transferred to a 0.45 µm nitrocellulose membrane and stained with Ponceau S to verify equal protein transfer. Membranes were blocked using casein and an avidin-biotin blocking kit (Vector Labs, Burlingame, CA), rinsed and incubated with a biotinylated monoclonal antibody against ActRIIB (R & D Systems, Minneapolis, MN) and an avidin-HRPO conjugate (Vector Labs).
Membranes were developed with SuperSignal West Dura enhanced chemiluminescent reagents (Pierce Biotechnology, Rockford, IL) and visualized using a chemiluminescent documentation system (Bio-Rad).
Cultured Cells
Satellite Cell Isolation and Culture
Satellite cells were isolated from adult male MSTN +/+ mice as described by Allen and his colleagues (1). Mice were anesthetized with intraperitoneal injection of Avertin (400 mg/kg) and sacrificed by cervical dislocation. The hindlimb muscles were quickly removed, minced and digested in protease solution (1.25 mg/mL of Pronase E in PBS, Sigma) for 1 hour at 37ºC. Satellite cells were separated from muscle fiber fragments and from tissue debris by differential centrifugation and then plated on fibronectin coated 60mm tissue culture plates (BD Biosciences, San Jose, CA). Cultures were maintained in a humidified environment maintained at 37ºC and 5% CO 2 . Satellite cells were grown in DMEM + 20% FBS + 1% antibiotic-antimycotic (AbAm) until reaching 80% confluence, at which time the media was changed to DMEM + 2% horse serum + 1% AbAm to induce differentiation into myotubes.
RT-qPCR
Myotubes were treated with different concentrations of recombinant murine myostatin (R & D Systems, Minneapolis, MN) in DMEM + 1% AbAm for 2 hours. RNA was isolated from myotubes using an RNeasy Mini kit (Qiagen, Valencia, CA), treated with DNase I and reverse transcribed using an Omniscript RT kit (Qiagen) and oligo(dT) 15 primers. cDNA was amplified using primers for col1α2 (forward: 5'-CCAGCGAAGAACTCATACAGC-3'; reverse: 5'-GGACACCCCTTCTACGTTGT-3') and β2-microglobulin (forward: 5'-ATGGGAAGCCGAACATACTG-3'; reverse: 5'-CAGTCTCAGTGGGGGTGAAT-3') using a SYBR Green I PCR system (Qiagen) with
Uracil DNA Glycosylase (Invitrogen) in an Opticon 2 real-time thermal cycler (Bio-Rad).
qPCR reactions were conducted in triplicate for each sample. C(t) values for col1α2
were normalized to β2-microglobulin (β2m) using the 2 -ΔΔC(t) method (32 and an HRPO conjugated secondary antibody (Pierce Biotechnology), and developed as described above. Following detection of procollagen I, membranes were stripped and reprobed using a monoclonal antibody against β-tubulin (Developmental Studies Hybridoma Bank, Iowa City, IA).
Statistical Analyses
Results are presented as mean ± SEM. KaleidaGraph 4.02 software (Synergy Software, Reading, PA) was used to conduct statistical analyses. Differences between groups were tested using a one-way ANOVA with α=0.05. Fisher's LSD post-hoc test was used to identify specific differences when significance was detected.
Results
Morphology
The 
Collagen Content of Muscles
The amino acid hydroxyproline makes up ~14% of the dry mass of fibrillar collagens (44) and is commonly used as an indicator of collagen content. The relative hydroxyproline content of EDL muscles of MSTN -/-was 75% less than MSTN +/+ mice (Table 1 and Figure 1A) . MSTN +/-mice had 59% less hydroxyproline than MSTN +/+ mice. For soleus muscles, no difference was observed for the relative amounts of hydroxyproline amongst the three genotypes (Table 1 and Figure 1B ).
Myostatin Mediated Type I Collagen Synthesis
The marked decrease in the collagen content of the EDL muscles from myostatin deficient mice lead us to hypothesize that myostatin induces the expression of type I collagen in muscle tissue. We found a dose dependent increase in col1α2 expression ( Figure 2A ) and procollagen I protein content ( Figure 2B ) of primary myotubes treated with myostatin. Similar results were observed in C 2 C 12 myotubes and primary fibroblasts isolated from mouse tendon (data not shown).
Contractile Properties
Myostatin deficiency had a more profound impact on the contractile properties of EDL muscles than soleus muscles ( 
Contraction-Induced Injury
During lengthening contractions, the average force developed by EDL muscles was not different, but compared with MSTN +/+ mice, the work done to lengthen the muscles was 12% and 37% less for MSTN +/-and MSTN -/-mice, respectively (Table 3) , indicating a decrease in the stiffness of these muscles. After the lengthening contraction protocol (LCP), muscles from MSTN -/-mice had a force deficit that was 15% greater than MSTN +/+ mice (Table 3 and Figure 4 ). During stretches of soleus muscles, the average force developed by MSTN -/-mice was approximately 18% greater than that of MSTN +/+ mice. During lengthening contractions of soleus muscles, no differences in the work done to stretch the muscles were observed. Following the LCP, the force deficits of soleus muscles were not different.
ActRIIB Content of EDL and Soleus Muscles
The deficiency of myostatin had a more profound impact on the morphological and contractile properties of EDL muscles than soleus muscles. Since myostatin appears to act systemically (71), the difference in the amount of ActRIIB present in EDL and soleus muscles was determined. Compared with soleus muscles, the amount of ActRIIB was greater in EDL muscles ( Figure 5 ).
Discussion
The P o of skeletal muscle can be increased by either hypertrophy of existing fibers or by hyperplasia. In either case, as whole muscle CSA increases, the angle of pennation of muscle fibers (θ) also increases (38) . The transmission of the force developed by single muscle fibers from tendon to tendon along the line of tension development of the muscle is proportional to the cosine of θ. As θ increases from 0º to 90º, the cosine of θ decreases from 1 to 0. Therefore, as a muscle undergoes hypertrophy or hyperplasia, the net force per CSA is expected to decrease. Our hypothesis that myostatin deficiency would increase the P o but decrease the sP o of muscles is supported by the observations of the contractile properties of the EDL muscles of MSTN -/-mice. In contrast, for soleus muscles, the complete deficiency of myostatin increased the P o less than that of the EDL muscle and had no effect on the sP o . Following contraction-induced injury to muscles, the immediate force deficit results from the mechanical disruption of the ultrastructure of sarcomeres (8, 18, 33, 34) . The magnitude of this force deficit is a function of strain and the work done to stretch the contractile component (CC) of muscle (8) . The aponeurosis (intramuscular tendon) and the tendon, composed chiefly of type I and III collagen (12, 22, 27) , form the series elastic component (SEC) of muscle (23) . A positive correlation exists between the collagen content and stiffness of a muscle (16, 19, 48) . During a lengthening contraction, the total displacement of the muscle is the sum of the displacement of the CC and the SEC, therefore displacement of the SEC protects the CC from contractioninduced injury. During a lengthening contraction, the protection afforded to the CC by the SEC increases as the displacement of the SEC relative to the CC increases.
Despite this potential for protection, if the strain and work done during a lengthening contraction are great enough, the SEC can become damaged and no longer provide protection for the CC. Consequently, an advantageous arrangement for a muscle is to have an SEC with a stiffness that allows for a moderate amount of displacement during a lengthening contraction, but not too compliant as to become damaged during a lengthening contraction. Our results suggest that for EDL muscles, the complete deficiency of myostatin decreases the stiffness of the SEC in such a way that the susceptibility to contraction-induced injury is increased.
The effect of myostatin deficiency on the structure and function of EDL and soleus muscles was quite different. Compared with the content of the primary myostatin receptor, ActRIIB, in the soleus muscles of MSTN +/+ mice, the content in the EDL muscles was ~ two-fold greater. The greater quantity of ActRIIB in the EDL muscles of MSTN +/+ mice appeared to make the EDL muscles more responsive than soleus muscles to the presence of myostatin. Consequently, with the absence of myostatin in the MSTN -/-mice, the EDL muscles experience a much greater relative increase in mass and number of fibers than experienced by the soleus muscles.
The treatment of muscle injuries and disease often involves a two-pronged therapeutic regimen of improving the strength of muscle and decreasing the formation of collagenous scar tissue (13, 49) . Much of the interest behind the potential use of myostatin inhibitors is the ability of these inhibitors to enhance the regeneration of skeletal muscle and also decrease the accumulation of scar tissue in murine models of muscle injuries and disease (17, 40, 45, (61) (62) (63) . Myostatin inhibitors may therefore be a useful therapeutic adjunct to traditional athletic training and physical therapy by directly improving contractility and decreasing fibrosis. The enhanced regenerative capacity of myostatin-deficient muscle is likely due to an increase in satellite cell activity, as myostatin is a negative regulator of satellite cell proliferation and migration (28, 39, 40, 56, 58, 62) . The increased satellite cell activity produced by the deficiency of myostatin does not explain how myostatin deficiency decreases the fibrosis normally present in dystrophic muscle (4, 5, 63 ) and following snake venom-induced muscle injury (40, 62) . Values are means ± SE. N = 6 muscles per genotype. P t = peak twitch force; sP t = specific P t ; TTPT = time to peak twitch tension; ½RT = half-relaxation time; dP/dt = 
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